Skip to main content

Amitifadine hydrochloride: Triple reuptake inhibitor treatment of depression

Publication ,  Journal Article
Marks, DM
Published in: Drugs of the Future
January 1, 2012

Amitifadine (EB-1010, DOV-21947) is a "triple reuptake inhibitor" that inhibits the reuptake of serotonin, norepinephrine and dopamine with relative in vitro potencies of 1:2:8. In addition to this in vitro receptor profile, in vivo microdialysis studies demonstrated that amitifadine increases extracellular concentrations of the three monoamines and reduces concentrations of monoamine metabolites. Amitifadine has also shown antidepressant potential in animal models, including the forced swim and tail suspension tests. As a result of these preclinical studies, amitifadine is currently in clinical development as an antidepressant and has demonstrated efficacy and tolerability in a randomized, placebo-controlled, proof-of-concept clinical trial in patients with major depressive disorder. The current monograph describes the chemical properties of amitifadine, as well as information gleaned from the preclinical and clinical studies to date. The premise behind the development of triple reuptake inhibitors is discussed. Copyright © 2012 Prous Science, S.A.U. or its licensors. All rights reserved.

Duke Scholars

Published In

Drugs of the Future

DOI

ISSN

0377-8282

Publication Date

January 1, 2012

Volume

37

Issue

4

Start / End Page

241 / 246

Related Subject Headings

  • Medicinal & Biomolecular Chemistry
  • 3214 Pharmacology and pharmaceutical sciences
  • 1115 Pharmacology and Pharmaceutical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Marks, D. M. (2012). Amitifadine hydrochloride: Triple reuptake inhibitor treatment of depression. Drugs of the Future, 37(4), 241–246. https://doi.org/10.1358/dof.2012.037.04.1782933
Marks, D. M. “Amitifadine hydrochloride: Triple reuptake inhibitor treatment of depression.” Drugs of the Future 37, no. 4 (January 1, 2012): 241–46. https://doi.org/10.1358/dof.2012.037.04.1782933.
Marks DM. Amitifadine hydrochloride: Triple reuptake inhibitor treatment of depression. Drugs of the Future. 2012 Jan 1;37(4):241–6.
Marks, D. M. “Amitifadine hydrochloride: Triple reuptake inhibitor treatment of depression.” Drugs of the Future, vol. 37, no. 4, Jan. 2012, pp. 241–46. Scopus, doi:10.1358/dof.2012.037.04.1782933.
Marks DM. Amitifadine hydrochloride: Triple reuptake inhibitor treatment of depression. Drugs of the Future. 2012 Jan 1;37(4):241–246.

Published In

Drugs of the Future

DOI

ISSN

0377-8282

Publication Date

January 1, 2012

Volume

37

Issue

4

Start / End Page

241 / 246

Related Subject Headings

  • Medicinal & Biomolecular Chemistry
  • 3214 Pharmacology and pharmaceutical sciences
  • 1115 Pharmacology and Pharmaceutical Sciences